25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

RNA (Avidity BiosciencesĀ Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Avidity BiosciencesĀ Inc together

I guess you are interested in Avidity BiosciencesĀ Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • šŸ“Š Fundamental Analysis (FA) – Avidity BiosciencesĀ Inc’s Financial Insights
  • šŸ“ˆ Technical Analysis (TA) – Avidity BiosciencesĀ Inc’s Price Targets

I'm going to help you getting a better view of Avidity BiosciencesĀ Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Avidity BiosciencesĀ Inc

I send you an email if I find something interesting about Avidity BiosciencesĀ Inc.

1. Quick Overview

1.1. Quick analysis of Avidity BiosciencesĀ Inc (30 sec.)










1.2. What can you expect buying and holding a share of Avidity BiosciencesĀ Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
4.0%

What is your share worth?

Current worth
$10.28
Expected worth in 1 year
$13.67
How sure are you?
36.0%

+ What do you gain per year?

Total Gains per Share
$3.39
Return On Investment
11.6%

For what price can you sell your share?

Current Price per Share
$29.17
Expected price per share
$21.56 - $38.00
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Avidity BiosciencesĀ Inc (5 min.)




Live pricePrice per Share (EOD)
$29.17
Intrinsic Value Per Share
$-48.18 - $-57.26
Total Value Per Share
$-37.90 - $-46.98

2.2. Growth of Avidity BiosciencesĀ Inc (5 min.)




Is Avidity BiosciencesĀ Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$1.3b$602m$767.4m56.0%

How much money is Avidity BiosciencesĀ Inc making?

Current yearPrevious yearGrowGrow %
Making money-$92.3m-$57.1m-$35.1m-38.1%
Net Profit Margin-4,425.7%-2,147.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Avidity BiosciencesĀ Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#49 / 881

Most Revenue
#412 / 881

Most Profit
#844 / 881

Most Efficient
#803 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Avidity BiosciencesĀ Inc?

Welcome investor! Avidity BiosciencesĀ Inc's management wants to use your money to grow the business. In return you get a share of Avidity BiosciencesĀ Inc.

First you should know what it really means to hold a share of Avidity BiosciencesĀ Inc. And how you can make/lose money.

Speculation

The Price per Share of Avidity BiosciencesĀ Inc is $29.17. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Avidity BiosciencesĀ Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Avidity BiosciencesĀ Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $10.28. Based on the TTM, the Book Value Change Per Share is $0.85 per quarter. Based on the YOY, the Book Value Change Per Share is $0.56 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Avidity BiosciencesĀ Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.90-3.1%-0.73-2.5%-0.47-1.6%-0.53-1.8%-0.40-1.4%-0.33-1.1%
Usd Book Value Change Per Share-0.81-2.8%0.852.9%0.561.9%0.602.0%0.491.7%0.391.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.81-2.8%0.852.9%0.561.9%0.602.0%0.491.7%0.391.3%
Usd Price Per Share29.52-36.35-13.01-22.15-23.06-18.45-
Price to Earnings Ratio-8.24--13.10--6.61--10.23--22.04--17.63-
Price-to-Total Gains Ratio-36.55--7.02-1,251.90-362.82-148.18-148.18-
Price to Book Ratio2.87-3.32-2.44-3.41-5.66-4.53-
Price-to-Total Gains Ratio-36.55--7.02-1,251.90-362.82-148.18-148.18-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share29.17
Number of shares34
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.850.49
Usd Total Gains Per Share0.850.49
Gains per Quarter (34 shares)28.7916.55
Gains per Year (34 shares)115.1766.19
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1011510506656
202302200132122
303463350199188
404614500265254
505765650331320
606916800397386
708067950463452
809219100530518
90103710250596584
100115211400662650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.025.00.00.0%1.025.08.02.9%
Book Value Change Per Share2.02.00.050.0%6.06.00.050.0%8.012.00.040.0%9.013.03.036.0%13.018.03.038.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.024.04.0%1.00.033.02.9%
Total Gains per Share2.02.00.050.0%6.06.00.050.0%8.012.00.040.0%9.013.03.036.0%13.018.03.038.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Avidity BiosciencesĀ Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.8080.847-195%0.564-243%0.597-235%0.487-266%0.389-308%
Book Value Per Share--10.28210.922-6%4.996+106%6.612+56%5.070+103%4.124+149%
Current Ratio--16.90916.545+2%11.147+52%13.075+29%15.822+7%13.349+27%
Debt To Asset Ratio--0.0890.089+0%0.128-30%0.107-17%0.099-10%0.187-52%
Debt To Equity Ratio--0.0980.098+0%0.150-35%0.122-19%0.111-12%0.130-25%
Dividend Per Share----0%-0%-0%-0%0.000-100%
Enterprise Value--5064453640.0005844355537.500-13%2136625950.000+137%3496041162.500+45%3403060267.500+49%3403060267.500+49%
Eps---0.896-0.733-18%-0.474-47%-0.531-41%-0.398-56%-0.333-63%
Ev To Ebitda Ratio---9.685-14.249+47%-8.218-15%-11.735+21%-24.746+156%-24.746+156%
Ev To Sales Ratio--804.904685.168+17%190.782+322%378.048+113%391.369+106%391.369+106%
Free Cash Flow Per Share---0.995-0.723-27%-0.298-70%-0.451-55%-0.337-66%-0.271-73%
Free Cash Flow To Equity Per Share---0.9800.928-206%0.657-249%0.656-249%0.523-287%0.447-319%
Gross Profit Margin--1.0001.0020%1.0050%1.0020%1.0010%1.0010%
Intrinsic Value_10Y_max---57.262----------
Intrinsic Value_10Y_min---48.181----------
Intrinsic Value_1Y_max---2.376----------
Intrinsic Value_1Y_min---2.332----------
Intrinsic Value_3Y_max---9.701----------
Intrinsic Value_3Y_min---9.210----------
Intrinsic Value_5Y_max---20.115----------
Intrinsic Value_5Y_min---18.450----------
Market Cap3515568400.000-9%3814928640.0004535369287.500-16%1567965200.000+143%2721408829.167+40%2809843617.500+36%2247874894.000+70%
Net Profit Margin---73.600-44.257-40%-21.470-71%-28.274-62%-21.625-71%-19.091-74%
Operating Margin---83.609-51.764-38%-24.082-71%-32.256-61%-24.024-71%-20.582-75%
Operating Ratio--84.60952.826+60%25.189+236%34.957+142%28.330+199%25.276+235%
Pb Ratio2.837-1%2.8713.324-14%2.439+18%3.407-16%5.662-49%4.529-37%
Pe Ratio-8.140+1%-8.238-13.095+59%-6.614-20%-10.232+24%-22.042+168%-17.634+114%
Price Per Share29.170-1%29.52036.345-19%13.010+127%22.152+33%23.057+28%18.446+60%
Price To Free Cash Flow Ratio-7.329+1%-7.417-14.061+90%-1.268-83%-9.537+29%-25.170+239%-20.136+171%
Price To Total Gains Ratio-36.113+1%-36.546-7.025-81%1251.897-103%362.818-110%148.178-125%148.178-125%
Quick Ratio--29.95528.446+5%18.326+63%21.806+37%21.588+39%17.953+67%
Return On Assets---0.079-0.062-22%-0.084+6%-0.078-1%-0.073-8%-0.072-10%
Return On Equity---0.087-0.068-22%-0.097+12%-0.088+1%-0.081-6%-0.076-13%
Total Gains Per Share---0.8080.847-195%0.564-243%0.597-235%0.487-266%0.389-308%
Usd Book Value--1328723000.0001369524500.000-3%602077250.000+121%814560833.333+63%621701200.000+114%505493120.000+163%
Usd Book Value Change Per Share---0.8080.847-195%0.564-243%0.597-235%0.487-266%0.389-308%
Usd Book Value Per Share--10.28210.922-6%4.996+106%6.612+56%5.070+103%4.124+149%
Usd Dividend Per Share----0%-0%-0%-0%0.000-100%
Usd Enterprise Value--5064453640.0005844355537.500-13%2136625950.000+137%3496041162.500+45%3403060267.500+49%3403060267.500+49%
Usd Eps---0.896-0.733-18%-0.474-47%-0.531-41%-0.398-56%-0.333-63%
Usd Free Cash Flow---128582000.000-91305750.000-29%-35950000.000-72%-55714083.333-57%-41425650.000-68%-33336320.000-74%
Usd Free Cash Flow Per Share---0.995-0.723-27%-0.298-70%-0.451-55%-0.337-66%-0.271-73%
Usd Free Cash Flow To Equity Per Share---0.9800.928-206%0.657-249%0.656-249%0.523-287%0.447-319%
Usd Market Cap3515568400.000-9%3814928640.0004535369287.500-16%1567965200.000+143%2721408829.167+40%2809843617.500+36%2247874894.000+70%
Usd Price Per Share29.170-1%29.52036.345-19%13.010+127%22.152+33%23.057+28%18.446+60%
Usd Profit---115773000.000-92305250.000-20%-57170250.000-51%-65064166.667-44%-48552500.000-58%-40074760.000-65%
Usd Revenue--1573000.0002231750.000-30%2717500.000-42%2454916.667-36%2300450.000-32%1987440.000-21%
Usd Total Gains Per Share---0.8080.847-195%0.564-243%0.597-235%0.487-266%0.389-308%
 EOD+3 -5MRQTTM+6 -32YOY+17 -213Y+16 -225Y+15 -2310Y+15 -25

3.3 Fundamental Score

Let's check the fundamental score of Avidity BiosciencesĀ Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.140
Price to Book Ratio (EOD)Between0-12.837
Net Profit Margin (MRQ)Greater than0-73.600
Operating Margin (MRQ)Greater than0-83.609
Quick Ratio (MRQ)Greater than129.955
Current Ratio (MRQ)Greater than116.909
Debt to Asset Ratio (MRQ)Less than10.089
Debt to Equity Ratio (MRQ)Less than10.098
Return on Equity (MRQ)Greater than0.15-0.087
Return on Assets (MRQ)Greater than0.05-0.079
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Avidity BiosciencesĀ Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.920
Ma 20Greater thanMa 5030.730
Ma 50Greater thanMa 10030.715
Ma 100Greater thanMa 20030.291
OpenGreater thanClose29.460
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Avidity BiosciencesĀ Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2025-06-20 14:35:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitĀ Avidity BiosciencesĀ Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareĀ Avidity BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • A Net Profit Margin of -7,360.0%Ā means thatĀ $-73.60 for each $1Ā in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Avidity BiosciencesĀ Inc:

  • The MRQ is -7,360.0%. The company is making a huge loss. -2
  • The TTM is -4,425.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-7,360.0%TTM-4,425.7%-2,934.3%
TTM-4,425.7%YOY-2,147.0%-2,278.7%
TTM-4,425.7%5Y-2,162.5%-2,263.3%
5Y-2,162.5%10Y-1,909.1%-253.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7,360.0%-91.7%-7,268.3%
TTM-4,425.7%-139.0%-4,286.7%
YOY-2,147.0%-194.4%-1,952.6%
3Y-2,827.4%-248.5%-2,578.9%
5Y-2,162.5%-343.3%-1,819.2%
10Y-1,909.1%-488.9%-1,420.2%
4.3.1.2. Return on Assets

Shows howĀ efficientĀ Avidity BiosciencesĀ Inc is using its assets to generate profit.

  • Above 5% is considered healthyĀ but always compareĀ Avidity BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • -7.9% Return on Assets means thatĀ Avidity BiosciencesĀ Inc generatedĀ $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Avidity BiosciencesĀ Inc:

  • The MRQ is -7.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.9%TTM-6.2%-1.8%
TTM-6.2%YOY-8.4%+2.3%
TTM-6.2%5Y-7.3%+1.1%
5Y-7.3%10Y-7.2%-0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.9%-11.6%+3.7%
TTM-6.2%-11.7%+5.5%
YOY-8.4%-11.4%+3.0%
3Y-7.8%-11.9%+4.1%
5Y-7.3%-12.1%+4.8%
10Y-7.2%-13.8%+6.6%
4.3.1.3. Return on Equity

Shows how efficient Avidity BiosciencesĀ Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareĀ Avidity BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • -8.7% Return on Equity means Avidity BiosciencesĀ Inc generated $-0.09Ā for eachĀ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Avidity BiosciencesĀ Inc:

  • The MRQ is -8.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.7%TTM-6.8%-2.0%
TTM-6.8%YOY-9.7%+3.0%
TTM-6.8%5Y-8.1%+1.4%
5Y-8.1%10Y-7.6%-0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.7%-13.5%+4.8%
TTM-6.8%-15.0%+8.2%
YOY-9.7%-14.5%+4.8%
3Y-8.8%-16.9%+8.1%
5Y-8.1%-17.9%+9.8%
10Y-7.6%-19.9%+12.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Avidity BiosciencesĀ Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresĀ how efficient Avidity BiosciencesĀ Inc is operatingĀ .

  • Measures how much profit Avidity BiosciencesĀ Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareĀ Avidity BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • An Operating Margin of -8,360.9%Ā means the company generated $-83.61 Ā for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Avidity BiosciencesĀ Inc:

  • The MRQ is -8,360.9%. The company is operating very inefficient. -2
  • The TTM is -5,176.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-8,360.9%TTM-5,176.4%-3,184.5%
TTM-5,176.4%YOY-2,408.2%-2,768.2%
TTM-5,176.4%5Y-2,402.4%-2,773.9%
5Y-2,402.4%10Y-2,058.2%-344.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,360.9%-229.2%-8,131.7%
TTM-5,176.4%-249.7%-4,926.7%
YOY-2,408.2%-208.4%-2,199.8%
3Y-3,225.6%-221.7%-3,003.9%
5Y-2,402.4%-344.1%-2,058.3%
10Y-2,058.2%-470.4%-1,587.8%
4.3.2.2. Operating Ratio

Measures how efficient Avidity BiosciencesĀ Inc is keepingĀ operating costsĀ low.

  • Below 1 is considered healthy (always compare toĀ Biotechnology industry mean).
  • An Operation Ratio of 84.61 means that the operating costs are $84.61 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Avidity BiosciencesĀ Inc:

  • The MRQ is 84.609. The company is inefficient in keeping operating costs low. -1
  • The TTM is 52.826. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ84.609TTM52.826+31.783
TTM52.826YOY25.189+27.637
TTM52.8265Y28.330+24.496
5Y28.33010Y25.276+3.054
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ84.6092.108+82.501
TTM52.8262.680+50.146
YOY25.1893.080+22.109
3Y34.9573.621+31.336
5Y28.3304.734+23.596
10Y25.2766.546+18.730
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Avidity BiosciencesĀ Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Avidity BiosciencesĀ Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toĀ Biotechnology industry mean).
  • A Current Ratio of 16.91Ā means the company has $16.91 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Avidity BiosciencesĀ Inc:

  • The MRQ is 16.909. The company is very able to pay all its short-term debts. +2
  • The TTM is 16.545. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ16.909TTM16.545+0.364
TTM16.545YOY11.147+5.398
TTM16.5455Y15.822+0.724
5Y15.82210Y13.349+2.472
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.9093.659+13.250
TTM16.5453.834+12.711
YOY11.1474.141+7.006
3Y13.0754.661+8.414
5Y15.8225.756+10.066
10Y13.3496.151+7.198
4.4.3.2. Quick Ratio

Measures if Avidity BiosciencesĀ Inc is able to pay off Short-term Debt but only usingĀ theĀ most liquid assets.

  • Above 1 is considered healthy butĀ always compareĀ Avidity BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • A Quick Ratio of 29.96Ā means the company can pay off $29.96 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Avidity BiosciencesĀ Inc:

  • The MRQ is 29.955. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 28.446. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ29.955TTM28.446+1.509
TTM28.446YOY18.326+10.120
TTM28.4465Y21.588+6.858
5Y21.58810Y17.953+3.635
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ29.9552.799+27.156
TTM28.4463.143+25.303
YOY18.3263.794+14.532
3Y21.8064.307+17.499
5Y21.5885.707+15.881
10Y17.9536.457+11.496
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Avidity BiosciencesĀ Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Ā of Avidity BiosciencesĀ IncĀ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareĀ Avidity BiosciencesĀ Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.09Ā means that Avidity BiosciencesĀ Inc assets areĀ financed with 8.9% credit (debt) and the remaining percentage (100% - 8.9%)Ā is financed by its owners/shareholders.Ā 

Let's take a look of the Debt to Asset Ratio trends of Avidity BiosciencesĀ Inc:

  • The MRQ is 0.089. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.089. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.089TTM0.089+0.000
TTM0.089YOY0.128-0.039
TTM0.0895Y0.099-0.010
5Y0.09910Y0.187-0.087
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0890.324-0.235
TTM0.0890.347-0.258
YOY0.1280.329-0.201
3Y0.1070.340-0.233
5Y0.0990.349-0.250
10Y0.1870.379-0.192
4.5.4.2. Debt to Equity Ratio

Measures ifĀ Avidity BiosciencesĀ Inc is able toĀ pay off its debts by usingĀ shareholders equity.

  • Below 2 is considered healthy butĀ always compareĀ Avidity BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • A Debt to Equity ratio of 9.8% means that company has $0.10 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Avidity BiosciencesĀ Inc:

  • The MRQ is 0.098. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.098. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.098TTM0.098+0.000
TTM0.098YOY0.150-0.052
TTM0.0985Y0.111-0.014
5Y0.11110Y0.130-0.019
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0980.379-0.281
TTM0.0980.435-0.337
YOY0.1500.412-0.262
3Y0.1220.446-0.324
5Y0.1110.460-0.349
10Y0.1300.509-0.379
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresĀ how much money you payĀ for each share forĀ every $1 in earnings Avidity BiosciencesĀ Inc generates.

  • Above 15 is considered overpriced butĀ always compareĀ Avidity BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • A PE ratio of -8.24 means the investor is paying $-8.24Ā for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Avidity BiosciencesĀ Inc:

  • The EOD is -8.140. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.238. Based on the earnings, the company is expensive. -2
  • The TTM is -13.095. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.140MRQ-8.238+0.098
MRQ-8.238TTM-13.095+4.857
TTM-13.095YOY-6.614-6.481
TTM-13.0955Y-22.042+8.947
5Y-22.04210Y-17.634-4.408
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.140-2.282-5.858
MRQ-8.238-2.062-6.176
TTM-13.095-2.541-10.554
YOY-6.614-3.722-2.892
3Y-10.232-3.754-6.478
5Y-22.042-6.100-15.942
10Y-17.634-6.653-10.981
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Avidity BiosciencesĀ Inc:

  • The EOD is -7.329. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.417. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -14.061. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.329MRQ-7.417+0.088
MRQ-7.417TTM-14.061+6.643
TTM-14.061YOY-1.268-12.793
TTM-14.0615Y-25.170+11.109
5Y-25.17010Y-20.136-5.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.329-3.101-4.228
MRQ-7.417-2.689-4.728
TTM-14.061-3.594-10.467
YOY-1.268-4.363+3.095
3Y-9.537-5.065-4.472
5Y-25.170-8.478-16.692
10Y-20.136-9.273-10.863
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofĀ Avidity BiosciencesĀ Inc is to cheap or to expensiveĀ compared to its book value.

  • At or below 1 is considered healthyĀ (always compare to Biotechnology industry mean).
  • A PB ratio of 2.87 means the investor is paying $2.87Ā for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Avidity BiosciencesĀ Inc:

  • The EOD is 2.837. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.871. Based on the equity, the company is underpriced. +1
  • The TTM is 3.324. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.837MRQ2.871-0.034
MRQ2.871TTM3.324-0.453
TTM3.324YOY2.439+0.885
TTM3.3245Y5.662-2.338
5Y5.66210Y4.529+1.132
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.8371.932+0.905
MRQ2.8711.848+1.023
TTM3.3242.119+1.205
YOY2.4392.469-0.030
3Y3.4072.526+0.881
5Y5.6623.667+1.995
10Y4.5294.351+0.178
4.6.2. Total Gains per Share

2.4. Latest News of Avidity BiosciencesĀ Inc

Does Avidity BiosciencesĀ Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Avidity BiosciencesĀ Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-17
12:42
Wolfe Research initiates Avidity Biosciences stock with outperform ratingRead
2025-06-15
00:53
Avidity Biosciences' SWOT analysis: innovative RNA tech targets rare disease stock potentialRead
2025-06-11
15:45
Raymond James bullish on biotech firms on favorable valuationRead
2025-06-10
15:25
Avidity Biosciences price target raised to $75 from $65 at ChardanRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Avidity BiosciencesĀ Inc.

4.8.1. Institutions holding Avidity BiosciencesĀ Inc

Institutions are holding 112.425% of the shares of Avidity BiosciencesĀ Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31FMR Inc12.95640.029415615064-894542-5.4183
2025-03-31HHG PLC9.48120.19811426696437368662.0116
2025-03-31T. Rowe Price Associates, Inc.9.40770.0412113380982952752.6739
2025-03-31BlackRock Inc8.22890.00629917471-14895-0.15
2025-03-31Wellington Management Company LLP8.03560.0559684556157845919.4725
2025-03-31Vanguard Group Inc7.66940.00499243205-188706-2.0007
2025-03-31RTW INVESTMENTS, LLC7.25773.9491874692681405610.2618
2025-03-31venBio Select Advisor LLC6.32683.513476250001250001.6667
2025-03-31RA Capital Management, LLC5.22773.1061630040800
2025-03-31State Street Corp3.58560.00534321360-280831-6.1021
2025-03-31Geode Capital Management, LLC2.28610.00642755246-52209-1.8597
2025-03-31Adage Capital Partners Gp LLC1.78050.11732145881-606063-22.0231
2025-03-31Casdin Capital, LLC1.69684.9328204500000
2025-03-31Orbimed Advisors, LLC1.50421.2758181288670000062.8995
2025-03-31Polar Capital Holdings PLC1.48430.3216178886851697740.6463
2025-03-31Bank of America Corp1.30640.003815744881395900781.6315
2025-03-31Driehaus Capital Management LLC1.05450.36171270931428733.4911
2025-03-31Siren, L.L.C.0.92151.84941110610-16685-1.4801
2025-03-31Charles Schwab Investment Management Inc0.84930.00571023578-5353-0.5202
2025-03-31Northern Trust Corp0.84510.00451018482-60952-5.6467
Total 91.905719.7876110764754+7721990+7.0%

4.9.2. Funds holding Avidity BiosciencesĀ Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Fidelity Growth Compy Commingled Pl S4.32120.21345207966706001.3742
2025-03-31T. Rowe Price New Horizons3.67970.81294434825-59973-1.3343
2025-03-31US Small-Cap Growth II Equity Comp3.67970.8129443482569290.1565
2025-04-30Fidelity Growth Company Fund3.0810.205937132791780005.035
2025-04-30Vanguard Total Stock Mkt Idx Inv3.0120.00693630008486771.3592
2025-03-31Vanguard Health Care Inv2.51460.2297303055767696828.7632
2025-05-31iShares Russell 2000 ETF2.36250.1433284732600
2025-03-31T. Rowe Price Health Sciences2.00440.57842415692-76436-3.0671
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.5290.0591184274697840.5338
2025-05-31SPDRĀ® S&P Biotech ETF1.38271.1003166644798560.595
2025-03-31Janus Henderson Global Life Sciences1.38251.0457166616941687433.3687
2025-03-31Janus Henderson Global Life Sciences D1.38251.04671666169219791.3368
2025-04-30Vanguard Small Cap Index1.17920.0331142114585150.6028
2025-03-31Janus Global Life Science AUSD1.12381.0459135436836182836.4548
2025-03-31Vanguard Explorer Inv1.11480.1998134357324317222.0985
2025-04-30Janus Henderson Glb Life Scn I2 USD1.11181.16871339932-14436-1.0659
2025-03-31T. Rowe Price New Horizons Tr-A1.03720.8176124999311808310.4322
2025-04-30Fidelity Growth Company K60.96170.21291158984115001.0022
2025-03-31Fidelity Small Cap Index0.94160.13861134815343413.1206
2025-03-31Janus Henderson Triton D0.93080.59611121746-11678-1.0303
Total 38.732710.467946680565+2054583+4.4%

5.3. Insider Transactions

Insiders are holding 5.167% of the shares of Avidity BiosciencesĀ Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-06-17Kathleen P GallagherSELL91130.24
2025-06-11W. Michael FlanaganSELL2000032.88
2025-06-02Kathleen P GallagherSELL587532.48
2025-05-01Kathleen P GallagherSELL587532.4
2025-04-01Kathleen P GallagherSELL587527.83
2025-03-20Michael F MacleanSELL793531.06
2025-03-20Sarah BoyceSELL3154031.06
2025-03-20Steven George HughesSELL957831.06
2025-02-03Kathleen P GallagherSELL587532.16
2025-01-21Arthur A LevinSELL187228.6
2025-01-21Michael F MacleanSELL328728.59
2025-01-21Sarah BoyceSELL1039728.59
2025-01-21Teresa MccarthySELL295928.59
2024-12-18Michael F MacleanSELL1115132.66
2024-12-18Sarah BoyceSELL3185532.66
2024-12-18W. Michael FlanaganSELL1274232.66
2024-12-16Teresa MccarthySELL2500033.26
2024-12-11W. Michael FlanaganSELL2400035.77
2024-11-19Arthur A LevinSELL332342.12
2024-11-18Teresa MccarthySELL2500041.14
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,459,075
Total Liabilities130,352
Total Stockholder Equity1,328,723
 As reported
Total Liabilities 130,352
Total Stockholder Equity+ 1,328,723
Total Assets = 1,459,075

Assets

Total Assets1,459,075
Total Current Assets1,434,975
Long-term Assets24,100
Total Current Assets
Cash And Cash Equivalents 254,203
Short-term Investments 1,125,674
Net Receivables 36,582
Other Current Assets 18,516
Total Current Assets  (as reported)1,434,975
Total Current Assets  (calculated)1,434,975
+/-0
Long-term Assets
Property Plant Equipment 20,566
Long-term Assets Other 3,534
Long-term Assets  (as reported)24,100
Long-term Assets  (calculated)24,100
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities84,865
Long-term Liabilities45,487
Total Stockholder Equity1,328,723
Total Current Liabilities
Short-term Debt 3,884
Accounts payable 6,633
Other Current Liabilities 60,370
Total Current Liabilities  (as reported)84,865
Total Current Liabilities  (calculated)70,887
+/- 13,978
Long-term Liabilities
Capital Lease Obligations 5,974
Long-term Liabilities  (as reported)45,487
Long-term Liabilities  (calculated)5,974
+/- 39,513
Total Stockholder Equity
Common Stock12
Retained Earnings -1,008,839
Accumulated Other Comprehensive Income 2,766
Other Stockholders Equity 2,334,784
Total Stockholder Equity (as reported)1,328,723
Total Stockholder Equity (calculated)1,328,723
+/-0
Other
Capital Stock12
Cash and Short Term Investments 1,379,877
Common Stock Shares Outstanding 129,232
Current Deferred Revenue13,978
Liabilities and Stockholders Equity 1,459,075
Net Debt -248,229
Net Invested Capital 1,328,723
Net Working Capital 1,350,110
Property Plant and Equipment Gross 29,348
Short Long Term Debt Total 5,974



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312011-12-31
> Total Assets 
32,680
62,408
55,570
52,607
131,200
125,100
116,793
105,509
88,852
0
0
0
96,907
92,678
355,355
346,133
333,898
314,752
290,523
425,917
427,580
421,135
420,801
430,539
638,800
613,976
610,784
573,163
628,555
951,474
1,347,425
1,640,771
1,563,895
1,459,075
1,459,0751,563,8951,640,7711,347,425951,474628,555573,163610,784613,976638,800430,539420,801421,135427,580425,917290,523314,752333,898346,133355,35592,67896,90700088,852105,509116,793125,100131,20052,60755,57062,40832,680
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
3,090
0
0
95,676
90,257
353,817
344,297
331,678
311,950
287,309
421,958
411,141
404,800
404,251
414,464
622,942
597,147
594,534
555,487
611,307
934,474
1,328,801
1,621,866
1,542,290
1,434,975
1,434,9751,542,2901,621,8661,328,801934,474611,307555,487594,534597,147622,942414,464404,251404,800411,141421,958287,309311,950331,678344,297353,81790,25795,676003,090000000000
       Cash And Cash Equivalents 
24,315
53,717
46,285
40,015
117,367
113,307
106,666
95,100
78,273
-3,090
0
0
94,578
88,751
352,446
341,142
328,141
301,273
276,423
410,013
405,543
139,262
125,106
143,699
340,396
118,710
153,880
85,650
185,082
471,400
575,751
370,187
219,868
254,203
254,203219,868370,187575,751471,400185,08285,650153,880118,710340,396143,699125,106139,262405,543410,013276,423301,273328,141341,142352,44688,75194,57800-3,09078,27395,100106,666113,307117,36740,01546,28553,71724,315
       Short-term Investments 
0
0
0
0
0
0
0
0
0
6,180
0
0
0
0
0
0
6,679
6,641
3,035
3,016
85,095
257,809
273,112
261,849
270,331
467,590
422,623
456,933
410,269
444,473
723,295
1,218,406
1,281,629
1,125,674
1,125,6741,281,6291,218,406723,295444,473410,269456,933422,623467,590270,331261,849273,112257,80985,0953,0163,0356,6416,6790000006,180000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,200
1,200
1,400
900
900
900
1,100
1,300
2,100
1,000
1,100
1,000
1,905
1,575
15,714
19,210
28,222
36,582
36,58228,22219,21015,7141,5751,9051,0001,1001,0002,1001,3001,1009009009001,4001,2001,2000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,200
0
-1,400
-900
-900
0
0
0
0
-1,000
-1,100
-1,000
0
0
-15,714
0
0
0
000-15,71400-1,000-1,100-1,0000000-900-900-1,4000-1,2000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
-3,090
0
0
1,231
2,421
1,538
1,836
2,220
2,802
3,214
3,959
16,439
16,335
16,550
16,075
15,858
16,829
16,250
17,676
17,248
17,000
18,624
18,905
21,605
24,100
24,10021,60518,90518,62417,00017,24817,67616,25016,82915,85816,07516,55016,33516,4393,9593,2142,8022,2201,8361,5382,4211,23100-3,090000000000
       Property Plant Equipment 
4,046
3,192
3,086
2,966
3,113
3,000
2,749
2,775
2,480
0
0
0
631
558
771
1,295
1,468
2,187
2,556
3,220
15,589
15,286
15,884
15,301
15,009
16,104
15,531
17,037
16,652
16,280
15,465
15,792
18,289
20,566
20,56618,28915,79215,46516,28016,65217,03715,53116,10415,00915,30115,88415,28615,5893,2202,5562,1871,4681,2957715586310002,4802,7752,7493,0003,1132,9663,0863,1924,046
       Intangible Assets 
1,173
1,146
1,075
1,023
991
1,044
975
1,418
1,447
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000001,4471,4189751,0449911,0231,0751,1461,173
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
-3,090
0
0
600
1,863
767
541
752
364
407
488
599
548
415
523
598
474
424
344
301
425
364
3,113
3,316
3,534
3,5343,3163,1133644253013444244745985234155485994884073647525417671,86360000-3,090000000000
> Total Liabilities 
29,268
41,872
39,956
42,584
40,591
38,003
19,021
18,320
21,299
0
0
0
162,264
26,676
25,059
25,969
27,675
28,636
26,043
31,040
46,150
45,427
46,450
53,557
60,725
55,061
51,606
55,695
127,791
120,575
126,389
137,391
138,936
130,352
130,352138,936137,391126,389120,575127,79155,69551,60655,06160,72553,55746,45045,42746,15031,04026,04328,63627,67525,96925,05926,676162,26400021,29918,32019,02138,00340,59142,58439,95641,87229,268
   > Total Current Liabilities 
15,459
16,074
16,972
20,190
18,354
12,506
8,028
7,421
10,284
0
0
0
10,236
11,341
11,620
13,680
14,587
17,514
16,338
22,418
29,658
30,920
33,687
42,666
51,908
48,085
45,244
48,716
80,680
74,955
84,212
91,333
98,018
84,865
84,86598,01891,33384,21274,95580,68048,71645,24448,08551,90842,66633,68730,92029,65822,41816,33817,51414,58713,68011,62011,34110,23600010,2847,4218,02812,50618,35420,19016,97216,07415,459
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
2,774
2,780
0
689
2,780
951
914
877
3,538
5,088
6,136
6,180
6,210
6,258
6,302
7,204
7,278
3,726
7,530
3,804
3,844
3,884
3,8843,8443,8047,5303,7267,2787,2046,3026,2586,2106,1806,1365,0883,5388779149512,78068902,7802,774000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
2,774
2,780
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000002,7802,774000000000000
       Accounts payable 
3,278
3,151
3,597
5,348
3,531
2,632
3,027
2,044
4,033
0
0
0
2,308
3,540
5,399
6,028
7,745
10,412
8,488
11,904
2,806
18,821
20,512
26,375
4,637
3,908
5,653
5,550
8,809
2,349
8,889
7,662
8,461
6,633
6,6338,4617,6628,8892,3498,8095,5505,6533,9084,63726,37520,51218,8212,80611,9048,48810,4127,7456,0285,3993,5402,3080004,0332,0443,0272,6323,5315,3483,5973,1513,278
       Other Current Liabilities 
11,486
12,471
13,016
14,433
14,398
9,611
4,738
5,336
6,251
0
0
0
1,314
641
1,361
2,432
3,152
2,745
3,353
6,253
27,960
-9,105
-9,857
-7,277
60,850
59,715
52,431
56,823
36,228
42,777
41,096
60,207
64,726
60,370
60,37064,72660,20741,09642,77736,22856,82352,43159,71560,850-7,277-9,857-9,10527,9606,2533,3532,7453,1522,4321,3616411,3140006,2515,3364,7389,61114,39814,43313,01612,47111,486
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
152,028
15,335
13,439
12,289
13,088
11,122
9,705
8,622
16,492
14,507
12,763
10,891
8,817
6,976
6,362
6,979
47,111
45,620
42,177
46,058
40,918
45,487
45,48740,91846,05842,17745,62047,1116,9796,3626,9768,81710,89112,76314,50716,4928,6229,70511,12213,08812,28913,43915,335152,028000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
1,098
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,0980000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
-2,381
-2,483
679
0
-1,842
0
0
0
8,191
6,803
5,685
5,095
1,372
718
3,211
3,377
2,574
5,421
852
3,797
2,957
2,090
2,0902,9573,7978525,4212,5743,3773,2117181,3725,0955,6856,8038,191000-1,8420679-2,483-2,381000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
45
45
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000004545000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
1,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,3000000000000000
> Total Stockholder Equity
3,412
20,536
15,614
10,023
90,609
87,097
97,772
87,189
67,553
-8,436
0
0
-65,357
66,002
330,296
320,164
306,223
286,116
264,480
394,877
381,430
375,708
374,351
376,982
578,075
558,915
559,178
517,468
500,764
830,899
1,221,036
1,503,380
1,424,959
1,328,723
1,328,7231,424,9591,503,3801,221,036830,899500,764517,468559,178558,915578,075376,982374,351375,708381,430394,877264,480286,116306,223320,164330,29666,002-65,35700-8,43667,55387,18997,77287,09790,60910,02315,61420,5363,412
   Common Stock
253
382
372
377
486
495
495
494
456
0
0
0
0
2
4
4
4
4
4
5
5
5
5
5
7
7
7
7
8
10
11
12
12
12
121212111087777555554444420000456494495495486377372382253
   Retained Earnings Total Equity0000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
-41,129
0
0
-1,643
-1,727
-1,800
-1,901
-5
-3
0
-1
-187
-2,026
-2,986
-3,463
-2,698
-1,529
-2,666
-1,878
125
-464
-453
7,102
2,902
2,766
2,7662,9027,102-453-464125-1,878-2,666-1,529-2,698-3,463-2,986-2,026-187-10-3-5-1,901-1,800-1,727-1,64300-41,129000000000
   Capital Surplus 00000000000000000000-42,6940000000000000
   Treasury Stock0000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
-176,249
-42,650
369,118
370,425
372,764
376,499
381,213
540,884
566,161
596,513
641,806
688,513
939,310
971,375
1,019,800
1,029,660
1,071,395
1,470,972
1,931,890
2,287,076
2,315,111
2,334,784
2,334,7842,315,1112,287,0761,931,8901,470,9721,071,3951,029,6601,019,800971,375939,310688,513641,806596,513566,161540,884381,213376,499372,764370,425369,118-42,650-176,249000000000000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue10,897
Cost of Revenue-2,776
Gross Profit10,8978,121
 
Operating Income (+$)
Gross Profit10,897
Operating Expense-389,833
Operating Income-378,936-378,936
 
Operating Expense (+$)
Research Development303,593
Selling General Administrative86,240
Selling And Marketing Expenses0
Operating Expense389,833389,833
 
Net Interest Income (+$)
Interest Income56,882
Interest Expense-0
Other Finance Cost-0
Net Interest Income56,882
 
Pretax Income (+$)
Operating Income-378,936
Net Interest Income56,882
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-322,302-435,570
EBIT - interestExpense = -378,936
-322,302
-322,302
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-378,936-322,302
Earnings Before Interest and Taxes (EBITDA)-376,160
 
After tax Income (+$)
Income Before Tax-322,302
Tax Provision-0
Net Income From Continuing Ops-322,302-322,302
Net Income-322,302
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses389,833
Total Other Income/Expenses Net56,634-56,882
 

Technical Analysis of Avidity BiosciencesĀ Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Avidity BiosciencesĀ Inc. The general trend of Avidity BiosciencesĀ Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Avidity BiosciencesĀ Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Avidity BiosciencesĀ Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportĀ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceĀ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Avidity BiosciencesĀ Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 36.63 < 37.04 < 38.00.

The bearish price targets are: 25.58 > 22.24 > 21.56.

Know someone who trades $RNA? Share this with them.šŸ‘‡

Avidity BiosciencesĀ Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theĀ moving averageĀ of the selected period.

  • Moving averages are laggingĀ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Avidity BiosciencesĀ Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Avidity BiosciencesĀ Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theĀ momentumĀ of theĀ selected period based on two moving averages.

  • MACD is aĀ lagging momentumĀ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Avidity BiosciencesĀ Inc. The current macd is -0.63054835.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Avidity BiosciencesĀ Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Avidity BiosciencesĀ Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Avidity BiosciencesĀ Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Avidity BiosciencesĀ Inc Daily Moving Average Convergence/Divergence (MACD) ChartAvidity BiosciencesĀ Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Avidity BiosciencesĀ Inc. The current adx is 19.62.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Avidity BiosciencesĀ Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Avidity BiosciencesĀ Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsĀ the current trend.
  • ShowsĀ potential entry signals.
  • ShowsĀ Ā potential exit signals.
  • Can be used to placeĀ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Avidity BiosciencesĀ Inc. The current sar is 30.02.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Avidity BiosciencesĀ Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumĀ indicator, meaning the signals are instant.
  • RangesĀ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Avidity BiosciencesĀ Inc. The current rsi is 43.92. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Avidity BiosciencesĀ Inc Daily Relative Strength Index (RSI) ChartAvidity BiosciencesĀ Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesĀ a certain price to multiple prices ranging over time.

  • LeadingĀ momentumĀ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesĀ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Avidity BiosciencesĀ Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Avidity BiosciencesĀ Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Avidity BiosciencesĀ Inc Daily Stochastic Oscillator ChartAvidity BiosciencesĀ Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Ā the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Avidity BiosciencesĀ Inc. The current cci is -58.31712041.

Avidity BiosciencesĀ Inc Daily Commodity Channel Index (CCI) ChartAvidity BiosciencesĀ Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Avidity BiosciencesĀ Inc. The current cmo is -16.1114359.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Avidity BiosciencesĀ Inc Daily Chande Momentum Oscillator (CMO) ChartAvidity BiosciencesĀ Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Ā Shows the current price relative to the highest high over the last 14 days.
Ā 

  • Lagging momentum indicator
  • Ranging between 0 andĀ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Avidity BiosciencesĀ Inc. The current willr is -63.60248447.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Avidity BiosciencesĀ Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Avidity BiosciencesĀ Inc Daily Williams %R ChartAvidity BiosciencesĀ Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldĀ 

Score

Let's take a look at the Bollinger Bands of Avidity BiosciencesĀ Inc.

Avidity BiosciencesĀ Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Avidity BiosciencesĀ Inc. The current atr is 1.64696642.

Avidity BiosciencesĀ Inc Daily Average True Range (ATR) ChartAvidity BiosciencesĀ Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Ā Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Avidity BiosciencesĀ Inc. The current obv is 36,996,439.

Avidity BiosciencesĀ Inc Daily On-Balance Volume (OBV) ChartAvidity BiosciencesĀ Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Avidity BiosciencesĀ Inc. The current mfi is 22.06.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Avidity BiosciencesĀ Inc Daily Money Flow Index (MFI) ChartAvidity BiosciencesĀ Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Avidity BiosciencesĀ Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-03BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Avidity BiosciencesĀ Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Avidity BiosciencesĀ Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.920
Ma 20Greater thanMa 5030.730
Ma 50Greater thanMa 10030.715
Ma 100Greater thanMa 20030.291
OpenGreater thanClose29.460
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Avidity BiosciencesĀ Inc with someone you think should read this too:
  • Are you bullish or bearish on Avidity BiosciencesĀ Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Avidity BiosciencesĀ Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Avidity BiosciencesĀ Inc

I send you an email if I find something interesting about Avidity BiosciencesĀ Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Avidity BiosciencesĀ Inc.

Receive notifications about Avidity BiosciencesĀ Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.